COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

mRNA vaccines offer clear advantages and disadvantages ... “In addition, advances in delivery technologies over current gold-standard LNP approaches to improve immunogenicity and reduce dosing ...

MRNA-1273.213 is under clinical development by Moderna and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

信使核糖核酸(messenger ribonucleic acid, mRNA)是一种极具潜力的治疗药物, 在免疫学、肿瘤学、疫苗和先天性代谢疾病等研究领域具有广阔前景。但由于其自身不稳定且易被核酸酶降解所以需要高效的递送载体。脂质纳米颗粒(lipid nanoparticle, LNP)具有易于配制、稳定性高 ...

Engineers have developed a lipid nanoparticle (LNP) that delivers mRNA therapeutic ... the delivery molecules that helped get the mRNA of the COVID vaccine into cells, and their ability to reach ...

The vaccine – developed by researchers at the University of Florida (UF) in the US – is based on mRNA taken from the patient’s tumour that is delivered in a lipid nanoparticle (LNP ...

But compared to standard lipid nanoparticles used in mRNA vaccines, the new bubbles—dubbed LNP 55—were 150 times more likely to home in on their target. In two mouse models of pre-eclampsia, a single ...

Mandy Cohen, director of the U.S. Centers for Disease Control and Prevention (CDC), pointed to mRNA as a preferred platform for the shot since vaccines can be developed and distributed quickly.